Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd., commonly referred to as Glenmark, is a prominent global player in the pharmaceutical industry, headquartered in India. Founded in 1977, the company has established a strong presence in various operational regions, including North America, Europe, and emerging markets. Glenmark focuses on the development and manufacturing of innovative generics, specialty pharmaceuticals, and over-the-counter products. With a diverse portfolio that includes formulations in therapeutic areas such as dermatology, oncology, and respiratory, Glenmark is recognised for its commitment to research and development. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of new therapies. Glenmark's dedication to quality and innovation has positioned it as a trusted name in the pharmaceutical sector, making notable strides in both domestic and international markets.
DitchCarbon Score
How does Glenmark Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glenmark Pharmaceuticals's score of 50 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Glenmark Pharmaceuticals's reported carbon emissions
In 2023, Glenmark Pharmaceuticals reported total greenhouse gas emissions of approximately 12703000 kg CO2e for Scope 1, 64812000 kg CO2e for Scope 2, and 175069000 kg CO2e for Scope 3. This reflects a commitment to addressing climate change through significant emissions reduction targets. The company aims to reduce its absolute Scope 1 and 2 emissions by 35% by FY2035, using FY2021 as the baseline year. Additionally, Glenmark has set a target to decrease Scope 3 emissions from purchased goods and services, fuel and energy-related activities, downstream transportation and distribution, and investments by 28% per ton of pharmaceutical products within the same timeframe. Glenmark's emissions data indicates a proactive approach to sustainability, with a focus on reducing its carbon footprint in line with industry standards. The targets are classified as "Well-below 2°C," aligning with global climate goals. The company has not yet committed to a net-zero target but continues to work towards substantial reductions in its greenhouse gas emissions across all scopes.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 11,713,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,231,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 3,277,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glenmark Pharmaceuticals is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
